Send the following on WhatsApp
Continue to Chat免疫療法使轉移性大腸直腸癌(mCRC)患者 PFS 延長一倍——ASCO20 焦點 https://geneonline.news/pembrolizumab-msi-h-mcrc/?variant=zh-cn
免疫療法使轉移性大腸直腸癌(mCRC)患者 PFS 延長一倍——ASCO20 焦點 https://geneonline.news/pembrolizumab-msi-h-mcrc/?variant=zh-cn